πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 379 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11633479

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11633480

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11612657

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11590229

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11549109

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11530408

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11525138

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11504391

Modified RNA agents with reduced off-target effect

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11492623

Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11446380

Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11434487

Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and m

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11427822

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11419942

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11406716

Modified RNAi agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11408001

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11401517

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11400158

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11382979

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11332743

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11324820

Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11326166

Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11319539

Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11312957

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11306315

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted